Literature DB >> 17762922

Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy.

Florian Sterzing1, Christian Grehn, Julien Dinkel, Robert Krempien, Gernot Hartung, Jürgen Debus, Wolfgang Harms.   

Abstract

CASE REPORT: A 45-year-old patient with cervix carcinoma received combined radiochemotherapy including cisplatin. After a cumulative dose of 240 mg/m(2) the patient suddenly became somnolent and developed a severe tetraparesis and generalized seizures. After ruling out intracranial bleeding, cerebral metastases as well as infectious and metabolic causes of this condition, a severe toxic encephalopathy was diagnosed based on the clinical findings and MRI scans. After symptomatic treatment on the intensive care unit all symptoms were completely reversible.
CONCLUSION: Toxic encephalopathy is a rare but dramatic complication of various cytostatic drugs. With the widespread use of cisplatin this rare disorder should be kept in mind.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762922     DOI: 10.1007/s00066-007-1732-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  8 in total

1.  Pineal parenchymal tumors. Management with interstitial iodine-125 radiosurgery.

Authors:  Mohammad Maarouf; Faycal El Majdoub; Christian Bührle; Jürgen Voges; Ralph Lehrke; Martin Kocher; Stefan Hunsche; Harald Treuer; Volker Sturm
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

2.  Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.

Authors:  Katrien Vandecasteele; Wilfried De Neve; Werner De Gersem; Louke Delrue; Leen Paelinck; Amin Makar; Valérie Fonteyne; Carlos De Wagter; Geert Villeirs; Gert De Meerleer
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

3.  Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin?

Authors:  Mihály Patyánik; Csaba Nemeskéri; Zsuzsa Póti; Dániel Sinkó; Csilla Pesznyák; Réka Király; Róbert Kois; Arpád Mayer
Journal:  Strahlenther Onkol       Date:  2009-09-12       Impact factor: 3.621

4.  Long-term results of radiotherapy in primary carcinoma of the vagina.

Authors:  Stefan Hegemann; Ulrich Schäfer; Ralph Lellé; Normann Willich; Oliver Micke
Journal:  Strahlenther Onkol       Date:  2009-03-28       Impact factor: 3.621

5.  Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma. Long-term results of a phase III randomized trial.

Authors:  Viorica Nagy; Ovidiu Coza; Claudia Ordeanu; Alexandru Trăilă; Alin Rancea; Nicolae Todor; Nicolae Ghilezan
Journal:  Strahlenther Onkol       Date:  2009-03-28       Impact factor: 3.621

6.  Developing central nervous system and vulnerability to platinum compounds.

Authors:  G Bernocchi; M G Bottone; V M Piccolini; V Dal Bo; G Santin; S A De Pascali; D Migoni; F P Fanizzi
Journal:  Chemother Res Pract       Date:  2011-02-15

7.  Chemotherapy related encephalopathy in a patient with Stage IV cervical carcinoma treated with cisplatin and 5-fluorouracil: a case report.

Authors:  Amy L Chue; Indrajit N Fernando; Syed A Hussain; David A Yates
Journal:  Cases J       Date:  2009-07-30

8.  Neurotoxic Effects of Platinum Compounds: Studies in vivo on Intracellular Calcium Homeostasis in the Immature Central Nervous System.

Authors:  Graziella Bernocchi; Francesco P Fanizzi; Sandra A De Pascali; Valeria M Piccolini; Caterina Gasperini; Violetta Insolia; Maria Grazia Bottone
Journal:  Toxics       Date:  2015-06-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.